A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations

• ClinicalTrials.gov Identifier: NCT03051893
• Recruitment Status: Completed
• First Posted: February 14, 2017
• Last Update Posted: February 14, 2017
• Sponsor: Diurnal Limited
• Collaborator: Simbec Research
• Information provided by (Responsible Party): Diurnal Limited

Study Description

Brief Summary:

This was an open label, randomised, single dose study, comprising Part A (undertaken in two separate three-period crossover cohorts denoted as A1 and A2) and Part B (undertaken in one four-period crossover cohort), to evaluate the PK of Chronocort® in healthy male volunteers. The washout interval in both Part A and Part B was 1-week in between each treatment period.

Condition or disease	Intervention/treatment	Phase
Adrenal Insufficiency; Congenital Adrenal Hyperplasia	Drug: Chronocort	Phase 1

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 28 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Two-part Open Label, Randomised, Single Dose, Crossover Study in Healthy Volunteers to: (Part A) Compare the Pharmacokinetics of up to 6 Chronocort® Formulations, and (Part B) Determine the Dose Proportionality of a Selected Chronocort® Formulation at Three Dose Levels With an Additional Comparison With the Selected Formulation Dosed on Two Occasions Over a 24 Hour Period
• Study Start Date: February 2011
• Actual Primary Completion Date: April 2012
• Actual Study Completion Date: April 2012

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part A1; Three formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.	Drug: Chronocort; Modified formulation of hydrocortisone
Experimental: Part A2; Three additional formulations of Chronocort 30mg were administered to healthy volunteers, with a 7-day washout period between each dose. Each treatment was administered in a randomised, crossover manner.	Drug: Chronocort; Modified formulation of hydrocortisone
Experimental: Part B; The best formulation of Chronocort was then selected from Parts A1 & A2. This was then administered in four separate treatment periods, in dosages of 5mg, 10mg, 20mg and 30mg. Each treatment was administered in a randomised, crossover manner.	Drug: Chronocort; Modified formulation of hydrocortisone

Outcome Measures

Primary Outcome Measures :

1. To compare the Tmax of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. Parts A1 & A2 only [ Time Frame: 18 hours ]
   Time at maximum concentration in serum
2. To compare the Cmax of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. Parts A1 & A2 only [ Time Frame: 18 hours ]
   Maximum serum concentration
3. To compare the AUC0-t of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
   Area under the plasma concentration-time curve
4. To compare the AUC0-∞ of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
   Area under the plasma concentration-time curve from zero (0) hours to infinity (∞)
5. To compare the CL of six formulations of Chronocort® (30 mg, dosed at night) over an 18 hour period. [ Time Frame: 18 hours ]
   Drug clearance (CL) is defined as the volume of plasma in the vascular compartment cleared of drug per unit time

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 60 Years (Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
• Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))2.
• Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 14 days prior to the first dose.
• Subjects with negative urinary drugs of abuse screen determined within 14 days prior to the first dose.
• Subjects with negative HIV and Hepatitis B and C results.
• Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to the first dose.
• Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.

• Subjects and sexual partners used effective contraception methods during the trial and for 3 months after the last dose, for example:

  • Oral contraceptive and condom
  • Intra-uterine device (IUD) and condom
  • Diaphragm with spermicide and condom
• Subjects were available to complete the study.
• Subjects satisfied a medical examiner about their fitness to participate in the study.
• Subjects provided written informed consent to participate in the study.
• Subject continued to meet all screening inclusion criteria prior to dosing.
• Subjects with no clinically significant abnormal serum biochemistry, haematology and urine examination values including negative urinary drugs of abuse screen (including alcohol) prior to dosing.

Exclusion Criteria:

• A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
• Receipt of regular medication within 14 days prior to the first dose (including high dose vitamins, dietary supplements or herbal remedies).
• Receipt of any vaccination within 14 days prior to the first dose.
• Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
• Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections)
• Current or previous history of tuberculosis
• A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
• A clinically significant history or family history of psychiatric disorders/illnesses.
• A clinically significant history of drug or alcohol abuse.
• Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
• Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks. (N.B. The washout period between trials was defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
• Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to the first dose or have consumed any alcohol within the 48 hour period prior to the first dose.
• Donation of 450ml or more of blood within the previous 12 weeks.
• Subjects who smoked (or ex-smokers who had smoked within 6 months prior to first dose).
• Subjects who worked shifts (i.e. regularly alternated between days, afternoons and nights).

Contacts and Locations

Sponsors and Collaborators

Diurnal Limited

Simbec Research

Investigators

• Principal Investigator: Girish Sharma; Simbec Research

More Information

• Responsible Party: Diurnal Limited
• ClinicalTrials.gov Identifier: NCT03051893
• Other Study ID Numbers: DIUR-002
• First Posted: February 14, 2017
• Last Update Posted: February 14, 2017
• Last Verified: February 2017

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Adrenal Hyperplasia, Congenital; Adrenogenital Syndrome; Adrenal Insufficiency; Hyperplasia; Pathologic Processes; Adrenal Gland Diseases; Endocrine System Diseases; Disorders of Sex Development; Urogenital Abnormalities; Congenital Abnormalities; Genetic Diseases, Inborn; Steroid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Metabolic Diseases; Gonadal Disorders